26siRationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), but the effects of this approach on risk reduction and pulmonary vascular resistance (PVR) are not known. Objective: To test the hypothesis that a low-risk status would be determined by the reduction of PVR in PAH patients treated upfront with a combination of oral drugs. Methods. The study enrolled 181 treatment-naive PAH patients (81 % idiopathic) with a follow-up right heart catheterization at 6 months (IQR 144-363 days) after initial combination of endothelin receptor antagonist + phosphodiesterase-5 inhibitor drugs and clinical evaluation and risk assessments by European guidelines and REVEAL scores. Results. Initial co...
BACKGROUND: Upfront combination therapy with ambrisentan and tadalafil has been reported to improve ...
International audienceTreatment for pulmonary arterial hypertension (PAH) has been underpinned by si...
There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension (PAH...
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertens...
An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), ...
Rationale Demographic characteristics of pulmonary arterial hypertension (PAH) patients have changed...
open11siPulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availa...
BACKGROUND: Upfront combination therapy with ambrisentan and tadalafil has been reported to improve ...
BACKGROUND: Upfront combination therapy with ambrisentan and tadalafil has been reported to improve ...
International audienceTreatment for pulmonary arterial hypertension (PAH) has been underpinned by si...
There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension (PAH...
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertens...
An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), ...
Rationale Demographic characteristics of pulmonary arterial hypertension (PAH) patients have changed...
open11siPulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availa...
BACKGROUND: Upfront combination therapy with ambrisentan and tadalafil has been reported to improve ...
BACKGROUND: Upfront combination therapy with ambrisentan and tadalafil has been reported to improve ...
International audienceTreatment for pulmonary arterial hypertension (PAH) has been underpinned by si...
There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension (PAH...